Back to search

Japan· JP-6132008M2024

セフィキシム水和物

A cefixime product containing セフィキシム水和物, registered in Japan by 長生堂製薬, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.

On Japan’s NHI price listATC J01DD08

Checked against MHLW / PMDA (Japan) on

Informational only — not a medical device.

SOURCE REGISTER · JPMHLW / PMDA (Japan)normalisedセフィキシム水和物ATCJ01DD08REGISTER NO.JP-6132008M2024PACKS LISTED0CHECKEDSeptember 25, 2026

Where it is registered

Cefixime is registered in 13 of 19 countries.

Countries holding a registration under ATC J01DD08 (cefixime), each read from that country’s own register.

  • This record: Japan, from MHLW / PMDA (Japan)
  • 7 of them publish a price we can compare per daily dose

Cefixime · ATC J01DD08

13 / 19 countries

  • Canada
  • Czechiaprice
  • Finlandprice
  • Germany
  • Ireland
  • Italyprice
  • Japan
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of cefixime costs, country by country.

Normalised to the WHO defined daily dose (0.4 g), the median price runs from $1.31 in Spain to $2.20 in Italy — a ×1.7 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Cefixime · price per daily dose (0.4 g)

USD · FX 28 Sept 2026

  • IT Italy$2.20
  • ES Spain$1.31
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

MHLW / PMDA (Japan)
Active substance
セフィキシム水和物
Manufacturer
長生堂製薬
Country
Japan (JP)
ATC code
J01DD08
ATC class
Cefixime
Defined daily dose
0.4 g, O
Reimbursed
Yes
Source register
MHLW / PMDA (Japan)
Last checked
September 25, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

21 interactions on record for cefixime.

Graded by severity as the source publishes them — 20 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Cefixime · interactions on record

21 records

  • 20 moderate
  • 1 info

Most severe, free to view

  • Sodium picosulfateA06AB08moderate
  • NeomycinA07AA01moderate
  • StreptomycinA07AA04moderate
  • KanamycinA07AA08moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c1a780e0-81aa-4e7f-a48e-4d1a9b82a976
GET /v1/drugs/c1a780e0-81aa-4e7f-a48e-4d1a9b82a976?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "spec": "100mg1カプセル",
  "marks": "局",
  "source": "mhlw",
  "remarks": null,
  "yj_code": "6132008M2024",
  "category": "内用薬",
  "price_yen": 69.6,
  "generic_name": "セフィキシム水和物",
  "product_name_jp": null,
  "therapeutic_class": "6132",
  "transitional_expiry": null
}

See everything about cefixime.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.